Anti-CTLA-4 (Ipilimumab), Humanized Antibody

Anti-CTLA-4 (Ipilimumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a fully-humanized IgG1 monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). By binding to CTLA-4, it releases the inhibitory action on cytotoxic T-lymphocytes and thus destroys cancer cells. The original monoclonal antibody is approved by the FDA to treat metastatic melanoma, metastatic colorectal cancer, and hepatocellular carcinoma. The antibody is also recommended in combination therapy with Nivolumab for advanced renal cell carcinoma

Immunogen Sequence:Ipilimumab

Target Alternative Name:CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3, CTLA4

Species Reactivities:/

Tag Line:Fully-humanized IgG1 monoclonal antibody that binds with high affinity and inhibits cytotoxic T lymphocyte antigen-4 (CTLA-4). Inhibition of CTLA-4 activates T-lymphocyte and ultimately results in tumor cell death

Formulation:In PBS buffer, pH 7.2

Purification: /

Application:In vivo studies,Cell proliferation assay

Positive Control:/

Application And Usages:Cell proliferation assay, In vivo studies

Handling:The antibody solution should be gently mixed before use.